L. Moore

In Vitro Activities of Linezolid, Meropenem, and Quinupristin-Dalfopristin against Group C and G Streptococci, Including Vancomycin-Tolerant Isolates

T. Zaoutis, J. Klein, L. Moore, 2001, Antimicrobial Agents and Chemotherapy.

COMPARATIVE SAFETY AND IMMUNOGENICITY OF TWO YELLOW FEVER 17 D VACCINES ( ARILVAX AND YF-VAX ) IN A PHASE III MULTICENTER , DOUBLE-BLIND CLINICAL TRIAL

T. Monath, R. Shope, J. Tian, 2003 .

Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial.

T. Monath, R. Shope, J. Tian, 2002, The American journal of tropical medicine and hygiene.

Minimal inhibitory concentrations and minimal bactericidal concentrations of quinupristin/dalfopristin against clinical isolates of Corynebacterium jeikeium and Listeria monocytogenes.

B. Schneider, L. Moore, W. Holloway, 1997, The Journal of antimicrobial chemotherapy.

489 Concha

L. Moore, W. Holloway, J. M. Concha, 2001 .

1998 William J. Stickel Bronze Award. Antifungal activity of Melaleuca alternifolia (tea-tree) oil against various pathogenic organisms.

L. Moore, W. Holloway, J. M. Concha, 1998, Journal of the American Podiatric Medical Association.

Antifungal susceptibility testing of yeasts: a brief overview.

A. Espinel-Ingroff, D. Sheehan, C. D. Webb, 1993, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Evaluation of interpretive criteria of agar dilution and disk diffusion susceptibility tests for Neisseria gonorrhoeae.

D. Dryja, L. Moore, K. Furness, 1994, Diagnostic microbiology and infectious disease.

In vitro Activities of Six Antifungal Agents Against Aspergillus terreus and Saccharomyces cerevisiae

L. Muehlbauer, J. Klein, L. Moore, 2002 .